The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models

被引:5
|
作者
Kelly, Rachel [1 ]
Cairns, Andrew G. [2 ]
Aden, Jorgen [2 ]
Almqvist, Fredrik [2 ]
Bemelmans, Alexis-Pierre [3 ]
Brouillet, Emmanuel [3 ]
Patton, Tommy [1 ]
McKernan, Declan P. [1 ]
Dowd, Eilis [1 ]
机构
[1] Natl Univ Ireland Galway, Pharmacol & Therapeut & Galway Neurosci Ctr, Galway H91 W5P7, Ireland
[2] Umea Univ, Dept Chem, S-90187 Umea, Sweden
[3] Univ Paris Saclay, CNRS, CEA, Lab Malad Neurodegenerat,MIRCen, F-92265 Fontenay Aux Roses, France
基金
爱尔兰科学基金会; 瑞典研究理事会;
关键词
Parkinson's; alpha-synuclein; adeno-associated virus; AAV; phospho-alpha-synuclein; DOPAMINERGIC NEURON LOSS; PARKINSONS-DISEASE; NIGROSTRIATAL NEURODEGENERATION; MEDIATED OVEREXPRESSION; MESSENGER-RNA; CORRIDOR TASK; PHOSPHORYLATION; PESTICIDE; GENE;
D O I
10.3390/biom11111685
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Animal models of Parkinson's disease, in which the human alpha-synuclein transgene is overexpressed in the nigrostriatal pathway using viral vectors, are widely considered to be the most relevant models of the human condition. However, although highly valid, these models have major limitations related to reliability and variability, with many animals exhibiting pronounced alpha-synuclein expression failing to demonstrate nigrostriatal neurodegeneration or motor dysfunction. Therefore, the aim of this study was to determine if sequential intra-nigral administration of AAV-alpha-synuclein followed by the small alpha-synuclein aggregating molecule, FN075, would enhance or precipitate the associated alpha-synucleinopathy, nigrostriatal pathology and motor dysfunction in subclinical models. Rats were given unilateral intra-nigral injections of AAV-alpha-synuclein (either wild-type or A53T mutant) followed four weeks later by a unilateral intra-nigral injection of FN075, after which they underwent behavioral testing for lateralized motor functionality until they were sacrificed for immunohistological assessment at 20 weeks after AAV administration. In line with expectations, both of the AAV vectors induced widespread overexpression of human alpha-synuclein in the substantia nigra and striatum. Sequential administration of FN075 significantly enhanced the alpha-synuclein pathology with increased density and accumulation of the pathological form of the protein phosphorylated at serine 129 (pS129-alpha-synuclein). However, despite this enhanced alpha-synuclein pathology, FN075 did not precipitate nigrostriatal degeneration or motor dysfunction in these subclinical AAV models. In conclusion, FN075 holds significant promise as an approach to enhancing the alpha-synuclein pathology in viral overexpression models, but further studies are required to determine if alternative administration regimes for this molecule could improve the reliability and variability in these models.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Alpha-synuclein pathology in the olfactory pathways of dementia patients
    Hubbard, Paul S.
    Esir, Margaret M.
    Reading, Margaret
    McShane, Rupert
    Nagy, Zsuzsanna
    JOURNAL OF ANATOMY, 2007, 211 (01) : 117 - 124
  • [42] Alpha-synuclein pathology enhances peripheral and CNS immune responses to bacterial endotoxins
    Hartke, Anna-Sophia
    Schreiber, Cara S.
    Lau, Kristina
    Wiesweg, Ivo
    Waltl, Inken
    Kalinke, Ulrich
    Richter, Franziska
    Kaeufer, Christopher
    NEUROBIOLOGY OF DISEASE, 2025, 205
  • [43] Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein
    Howe, Jacob W.
    Sortwell, Caryl E.
    Duffy, Megan F.
    Kemp, Christopher J.
    Russell, Christopher P.
    Kubik, Michael
    Patel, Pooja
    Luk, Kelvin C.
    El-Agnaf, Omar M. A.
    Patterson, Joseph R.
    PARKINSONISM & RELATED DISORDERS, 2021, 89 : 41 - 47
  • [44] A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology
    Sehlin, Dag
    Roshanbin, Sahar
    Zachrisson, Olof
    Ingelsson, Martin
    Syvanen, Stina
    NEUROTHERAPEUTICS, 2025, 22 (02)
  • [45] Rapamycin attenuates nigral and hippocampal alpha-synuclein accumulation in AAV-mediated alpha-synuclein overexpression model of Parkinson's disease
    Cinar, E.
    Yalcin-Cakmakli, G.
    Ulusoy, A.
    Saka, E.
    Tel, B.
    Elibol, B.
    MOVEMENT DISORDERS, 2021, 36 : S332 - S332
  • [46] Investigating alpha-synuclein co-pathology in Alzheimer's disease bymeans of cerebrospinal fluid alpha-synuclein seed amplification assay
    Bellomo, Giovanni
    Toja, Andrea
    Paoletti, Federico Paolini
    Ma, Yihua
    Farris, Carly M.
    Gaetani, Lorenzo
    Salvadori, Nicola
    Chiasserini, Davide
    LidiaWojdala, Anna
    Concha-Marambio, Luis
    Parnetti, Lucilla
    ALZHEIMERS & DEMENTIA, 2024, 20 (04) : 2444 - 2452
  • [47] Passive Immunization in Alpha-Synuclein Preclinical Animal Models
    Folke, Jonas
    Ferreira, Nelson
    Brudek, Tomasz
    Borghammer, Per
    Van Den Berge, Nathalie
    BIOMOLECULES, 2022, 12 (02)
  • [48] An entropic expansion mechanism modulates small-molecule recognition by alpha-synuclein
    Mondal, Jagannath
    Menon, Sneha
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 8A - 8A
  • [49] Bacterial products initiation of alpha-synuclein pathology: an in vitro study
    Ioghen, Octavian Costin
    Gaina, Gisela
    Lambrescu, Ioana
    Manole, Emilia
    Pop, Sevinci
    Niculescu, Teodora Maria
    Mosoia, Oana
    Ceafalan, Laura Cristina
    Popescu, Bogdan Ovidiu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] Metal Catalyzed Oxidation of Alpha-Synuclein - A Role for Oligomerization in Pathology?
    Cole, N. B.
    CURRENT ALZHEIMER RESEARCH, 2008, 5 (06) : 599 - 606